Drug Profile
SYNT 002
Alternative Names: SYNT-002Latest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator Syntimmune
- Class
- Mechanism of Action Fc receptor antagonists; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Metabolic disorders
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for preclinical development in Metabolic-disorders in USA
- 02 Nov 2018 Syntimmune has been acquired by Alexion Pharmaceuticals
- 20 Mar 2017 Preclinical trials in Metabolic disorders in USA (unspecified route) before March 2017